$POAI
Predictive Oncology Inc.

2024 Q3 Form 10-Q Financial Statement

#000117184324004757 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $345.7K $278.7K
YoY Change -51.66% -43.13%
Cost Of Revenue $196.9K $153.0K
YoY Change 84.14% -4.25%
Gross Profit $148.8K $125.8K
YoY Change -75.54% -61.93%
Gross Profit Margin 43.04% 45.12%
Selling, General & Admin $1.829M $2.422M
YoY Change -37.34% -22.72%
% of Gross Profit 1229.66% 1925.67%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $33.18K $157.3K
YoY Change -78.75% -9.13%
% of Gross Profit 22.3% 125.09%
Operating Expenses $2.463M $3.315M
YoY Change -16.24% 4.81%
Operating Profit -$2.314M -$3.189M
YoY Change -26.64% -19.45%
Interest Expense $10.00 $360.00
YoY Change -95.08%
% of Operating Profit
Other Income/Expense, Net $30.56K $7.630K
YoY Change -405.6% -73.27%
Pretax Income -$2.283M -$3.181M
YoY Change -27.74% -18.92%
Income Tax
% Of Pretax Income
Net Earnings -$3.095M -$3.181M
YoY Change -2.17% -18.92%
Net Earnings / Revenue -895.23% -1141.37%
Basic Earnings Per Share -$0.48 -$0.68
Diluted Earnings Per Share -$0.48 -$0.68
COMMON SHARES
Basic Shares Outstanding 6.667M 4.102M
Diluted Shares Outstanding 6.396M 4.665M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.079M $5.332M
YoY Change -74.17% -63.89%
Cash & Equivalents $3.079M $5.332M
Short-Term Investments
Other Short-Term Assets $520.2K $597.7K
YoY Change -16.09% 56.79%
Inventory $504.4K $568.2K
Prepaid Expenses
Receivables $463.8K $387.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.567M $6.885M
YoY Change -66.22% -56.89%
LONG-TERM ASSETS
Property, Plant & Equipment $402.9K $910.2K
YoY Change -71.07% -41.23%
Goodwill
YoY Change
Intangibles $221.5K $238.7K
YoY Change -14.59% -10.31%
Long-Term Investments
YoY Change
Other Assets $102.5K $121.1K
YoY Change -17.4% -30.44%
Total Long-Term Assets $2.931M $3.702M
YoY Change -36.92% -25.92%
TOTAL ASSETS
Total Short-Term Assets $4.567M $6.885M
Total Long-Term Assets $2.931M $3.702M
Total Assets $7.498M $10.59M
YoY Change -58.73% -49.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.142M $1.563M
YoY Change -2.25% 54.22%
Accrued Expenses $1.517M $1.947M
YoY Change -16.21% 17.97%
Deferred Revenue $257.4K $269.9K
YoY Change -31.35% -57.01%
Short-Term Debt $195.8K $276.9K
YoY Change -24.7%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.817M $4.619M
YoY Change -8.51% 22.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.05K $13.66K
YoY Change -99.57% -99.45%
Total Long-Term Liabilities $10.05K $13.66K
YoY Change -99.57% -99.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.817M $4.619M
Total Long-Term Liabilities $10.05K $13.66K
Total Liabilities $5.531M $6.493M
YoY Change -15.11% 3.69%
SHAREHOLDERS EQUITY
Retained Earnings -$178.3M -$175.2M
YoY Change 8.5% 8.71%
Common Stock $66.67K $57.09K
YoY Change 65.3% 42.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.967M $4.094M
YoY Change
Total Liabilities & Shareholders Equity $7.498M $10.59M
YoY Change -58.73% -49.51%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$3.095M -$3.181M
YoY Change -2.17% -18.92%
Depreciation, Depletion And Amortization $33.18K $157.3K
YoY Change -78.75% -9.13%
Cash From Operating Activities -$3.173M -$3.218M
YoY Change 2.03% -9.97%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $6.480K
YoY Change -97.5%
Acquisitions
YoY Change
Other Investing Activities $32.00K
YoY Change
Cash From Investing Activities $32.00K -$6.480K
YoY Change -97.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 888.3K 3.359M
YoY Change 241.65%
NET CHANGE
Cash From Operating Activities -3.173M -3.218M
Cash From Investing Activities 32.00K -6.480K
Cash From Financing Activities 888.3K 3.359M
Net Change In Cash -2.253M 134.5K
YoY Change -20.95% -103.51%
FREE CASH FLOW
Cash From Operating Activities -$3.173M -$3.218M
Capital Expenditures $0.00 $6.480K
Free Cash Flow -$3.173M -$3.225M
YoY Change 2.03% -15.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1860983 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2188979 usd
CY2024Q2 us-gaap Liabilities
Liabilities
6493155 usd
CY2023Q4 us-gaap Liabilities
Liabilities
6145469 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
730005 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
279900 usd
us-gaap Gross Profit
GrossProfit
450105 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4764265 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5040511 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1995584 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1871560 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1024155 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
799340 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7426019 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7424211 usd
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
28118 usd
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
70780 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3571 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
-0 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1368 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
8261 usd
us-gaap Net Income Loss
NetIncomeLoss
-7400104 usd
us-gaap Net Income Loss
NetIncomeLoss
-7345170 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.7
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4363812
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3982384
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
159761 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
340383 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
125754 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001446159
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 pure
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 pure
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5331770 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8728660 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
387040 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
333697 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
568215 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
494374 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
597724 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
521700 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
6884749 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
10078431 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
910211 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1233910 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
238731 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
252457 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2432339 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2728355 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
121096 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
124096 usd
CY2024Q2 us-gaap Assets
Assets
10587126 usd
CY2023Q4 us-gaap Assets
Assets
14417249 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1563023 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1342027 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
276932 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
150408 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1946893 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1631702 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
8 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1376 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
269943 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
308091 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
561712 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
517427 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4618511 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3951031 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13661 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5459 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5708876
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4062853
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
57089 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
40629 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
179198077 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
175992242 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175161987 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167761883 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4093971 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8271780 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10587126 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14417249 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
278722 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
490110 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
698368 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
152968 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
330349 usd
us-gaap Gross Profit
GrossProfit
357985 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2137189 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2704527 usd
CY2024Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
893391 usd
CY2023Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
993042 usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
284421 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
429103 usd
CY2024Q2 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
162905 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
162905 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
3315001 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4289577 usd
us-gaap Operating Expenses
OperatingExpenses
7784004 usd
us-gaap Operating Expenses
OperatingExpenses
7874316 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3189247 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3959228 usd
CY2024Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
9461 usd
CY2023Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
28552 usd
CY2024Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1834 usd
CY2023Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
-0 usd
CY2024Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
359 usd
CY2023Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
7308 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3181261 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3923368 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4664771
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3996512
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8271780 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
734 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4218843 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
4053671 usd
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
99253 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
306 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3122002 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3181261 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4093971 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21765892 usd
CY2023Q1 poai Stock Issued During Period Value Issued For Services And Other Adjustments
StockIssuedDuringPeriodValueIssuedForServicesAndOtherAdjustments
201008 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
0 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
18554385 usd
CY2023Q2 poai Stock Issued During Period Value Issued For Services And Other Adjustments
StockIssuedDuringPeriodValueIssuedForServicesAndOtherAdjustments
68168 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5872 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3923368 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
14705057 usd
us-gaap Net Income Loss
NetIncomeLoss
-7400104 usd
us-gaap Net Income Loss
NetIncomeLoss
-7345170 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
326730 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
417989 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1040 usd
us-gaap Share Based Compensation
ShareBasedCompensation
15159 usd
poai Equity Instruments Issued For Management And Consulting
EquityInstrumentsIssuedForManagementAndConsulting
99253 usd
poai Equity Instruments Issued For Management And Consulting
EquityInstrumentsIssuedForManagementAndConsulting
79280 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-1368 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-8261 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
162905 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-20205 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-903 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
53343 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
99653 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
73841 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-36795 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
73024 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-47090 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
220996 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
66109 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
329330 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-401002 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-38148 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
25823 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
8202 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6634072 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7002033 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9510 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
279727 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
26018 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9510 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-305745 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3695848 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
573846 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
275098 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
150408 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3246692 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3396890 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7307778 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8728660 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22071523 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5331770 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14763745 usd
us-gaap Interest Paid Net
InterestPaidNet
1737 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2997181 usd
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
0 usd
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
794 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued1
StockIssued1
189896 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3920 usd
CY2024Q2 us-gaap Payable Preferred Stock Redeemed
PayablePreferredStockRedeemed
0 usd
CY2023Q2 us-gaap Payable Preferred Stock Redeemed
PayablePreferredStockRedeemed
794 usd
CY2024Q2 poai Number Of Tumor Samples
NumberOfTumorSamples
150000 pure
CY2024Q2 poai Number Of Tumor Samples
NumberOfTumorSamples
150000 pure
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175161987 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5331770 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4618511 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1860983 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6634072 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Accounting Policies and Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, fair value of long-lived assets for impairment analyses, the valuation allowance included in the deferred income tax calculation, accrued expenses, and fair value of derivative liabilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Note 1 to the annual consolidated financial statements contained in the Annual Report on Form 10-K filed with the SEC on March 28, 2024, describes the significant accounting policies and estimates used in preparation of the consolidated financial statements. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Concentration of Credit Risk</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalent balances with high quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As of June 30, 2024, accounts receivable from a single customer represented 11% of the Company’s total accounts receivable. As of December 31, 2023, accounts receivable from a single customer represented 16% of the Company’s total accounts receivable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
387040 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
333697 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
283604 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
313550 usd
CY2024Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
49165 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
66139 usd
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
313847 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
239998 usd
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 usd
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
254368 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
254376 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
568215 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
494374 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4764097 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4821980 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3853886 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3588070 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
910211 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1233910 usd
CY2024Q2 us-gaap Depreciation
Depreciation
157302 usd
CY2023Q2 us-gaap Depreciation
Depreciation
173100 usd
us-gaap Depreciation
Depreciation
313004 usd
us-gaap Depreciation
Depreciation
404289 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6863 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7035 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13726 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13700 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
13726 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
27451 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
27451 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
27451 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
27451 usd
CY2024Q2 poai Finitelived Intangible Asset Expected Amortization After Year Four
FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour
115201 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
238731 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
227762 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
220847 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
455403 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
434862 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M10D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y5M15D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
375487 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
857622 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
803724 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
827909 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
139022 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3003764 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
581069 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2422695 usd
CY2022Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
13833 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
953 usd
CY2023Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
12880 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
7308 usd
CY2023Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
5572 usd
CY2023Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
1376 usd
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1009 usd
CY2024Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
367 usd
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
359 usd
CY2024Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
8 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1806589
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
21.52
poai Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
poai Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0
poai Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
-0
poai Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
77285
poai Class Of Warrant Or Right Expired During Period Exercise Price
ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice
33.86
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1729304
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
20.97
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
307 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5872 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1040 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15159 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
182 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P10M
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3181261 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3923368 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7400104 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7345170 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4664771
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3996512
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4363812
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3982384
CY2024Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4664771
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3996512
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4363812
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3982384
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.7
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2024Q2 poai Number Of Tumor Samples
NumberOfTumorSamples
150000 pure
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
278722 usd
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
164165 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3181261 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
698368 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
326730 usd
us-gaap Net Income Loss
NetIncomeLoss
-7400104 usd
CY2024Q2 us-gaap Assets
Assets
10587126 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
490110 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
180135 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3923368 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
730005 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
417989 usd
us-gaap Net Income Loss
NetIncomeLoss
-7345170 usd
CY2023Q4 us-gaap Assets
Assets
14417249 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001171843-24-004757-index-headers.html Edgar Link pending
0001171843-24-004757-index.html Edgar Link pending
0001171843-24-004757.txt Edgar Link pending
0001171843-24-004757-xbrl.zip Edgar Link pending
ex_709256.htm Edgar Link pending
ex_709257.htm Edgar Link pending
ex_709258.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
poai-20240630.xsd Edgar Link pending
poai20240630_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
poai-20240630_cal.xml Edgar Link unprocessable
poai-20240630_def.xml Edgar Link unprocessable
poai-20240630_lab.xml Edgar Link unprocessable
poai-20240630_pre.xml Edgar Link unprocessable
poai20240630_10q_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending